Human Metapneumovirus (hMPV) Surge in 2025: Children Most Affected in Recent Indian Outbreak

In early 2025, India experienced a notable outbreak of Human Metapneumovirus (hMPV), a respiratory virus primarily impacting young children, with the highest incidence reported among those aged 1 to 2 years. This outbreak, documented comprehensively in a recent study published in The Lancet Regional Health – Southeast Asia, mirrors a seasonal surge that began in China in late 2024 and spread to India, drawing considerable public health attention due to its impact on respiratory illness in children and other vulnerable populations.

Key Findings of the 2025 hMPV Outbreak Study

Researchers from Indian Council of Medical Research (ICMR) and the Directorate of Public Health and Preventive Medicine, Government of Tamil Nadu, analyzed data collected under the Model for Integrated Influenza Surveillance in Tamil Nadu from 2019 through early 2025. Findings revealed:

• An overall hMPV positivity rate of 3.2% among tested respiratory samples in 2019-2023, with a slight increase in 2024-2025.

• Children under five, especially those aged 1-2 years, represented the group most commonly diagnosed with hMPV infection.

• Clinical presentation often mimicked influenza or acute respiratory illness, with fever and cough as predominant symptoms.

• No substantial change in hMPV’s epidemiological features was observed, indicating the outbreak was driven by known circulating strains rather than novel variants.

• The outbreak onset in India occurred in mid-January 2025, initially reported in states such as Gujarat and Puducherry, paralleling the epidemic curve observed in China the previous year.

Expert Insights and Global Context

Human Metapneumovirus, first identified in 2001, is a common cause of respiratory tract infections worldwide, particularly in young children, the elderly, and immunocompromised persons. Dr. Anita Desai, a pediatric pulmonologist at the All India Institute of Medical Sciences (not involved in the study), explained, “hMPV is a significant but often under-recognized pathogen that commonly causes bronchiolitis and pneumonia. It tends to peak seasonally in late winter and early spring and is transmitted primarily through respiratory droplets.”

Global surveillance data indicate that hMPV accounts for approximately 5–7% of hospitalizations for viral respiratory infections among children, comparable to respiratory syncytial virus (RSV) in some regions. In Europe and North America, hMPV infections peak during winter months, and in parts of Asia, including India and China, seasonal variations may reflect monsoonal patterns or shifts related to indoor congregation during colder weather.

Dr. Michael Chen, an infectious disease epidemiologist at the University of California, noted, “Unlike novel viruses with pandemic potential, hMPV evolves gradually with new variants related to prior strains. This means that while epidemics can cause healthcare strain, particularly among young children, pre-existing immunity usually prevents extensive severe disease in healthy populations.”

Public Health Implications and Surveillance Needs

The rise in hMPV cases in India early this year was associated with increased respiratory illnesses accounting for over six percent of such cases in some regions. Although no specific antiviral treatments or vaccines currently exist for hMPV, supportive care and preventive hygiene practices remain critical to control spread and complications.

The study emphasizes strengthened virus surveillance to monitor hMPV trends, detect unusual epidemiologic changes early, and guide public health strategies. Given the potential for co-infections with bacteria or other viruses complicating clinical outcomes, integrated respiratory infection monitoring is crucial.

Parents and caregivers should remain alert for symptoms like persistent cough, fever, difficulty breathing, or worsening respiratory distress in children, seeking timely medical care. Preventive measures such as frequent handwashing, respiratory etiquette, and avoiding close contact with sick individuals are recommended to reduce transmission risk.

Limitations and Perspectives

While the study provides valuable insights, limitations include potential under-detection due to asymptomatic or mild cases not presenting for testing, and the observational nature limiting causality assessment. Additional research to understand immunological responses, potential for reinfections, and better clinical interventions is needed.

Furthermore, while children were most affected, hMPV can cause illness across all ages, particularly severe in older adults and the immunocompromised, underscoring the need for comprehensive public health attention beyond pediatric populations.pubmed.ncbi.nlm.nih+1

What This Means for Daily Health Decisions

For the general public, awareness about hMPV highlights the importance of respiratory hygiene and timely healthcare access for respiratory symptoms. As hMPV symptoms resemble other respiratory infections like influenza and COVID-19, maintaining vaccination for preventable diseases, including flu and COVID-19, remains a key protective measure.

Monitoring evolving public health guidance based on surveillance outcomes can help individuals and healthcare providers navigate respiratory illness seasons more effectively to reduce severe outcomes.

Medical Disclaimer

This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References